Loading...
Taysha Gene Therapies Community
NasdaqGS:TSHA Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
Community Investing Ideas
FDA Meetings And TSHA-102 Trials Will Advance Approval
Key Takeaways Advancements in TSHA-102 trials and regulatory discussions could expedite approval and boost future revenue and investor confidence. Strategic alignment with regulatory and market priorities could enhance trial success, market adoption, and long-term revenue growth.
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
US$9.42
43.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
128.01% p.a.
Profit Margin
16.11%
Future PE
248.26x
Share price in 2028
US$11.49